325 related articles for article (PubMed ID: 10822383)
1. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.
Yuan ZQ; Sun M; Feldman RI; Wang G; Ma X; Jiang C; Coppola D; Nicosia SV; Cheng JQ
Oncogene; 2000 May; 19(19):2324-30. PubMed ID: 10822383
[TBL] [Abstract][Full Text] [Related]
2. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
[TBL] [Abstract][Full Text] [Related]
3. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells.
Liu AX; Testa JR; Hamilton TC; Jove R; Nicosia SV; Cheng JQ
Cancer Res; 1998 Jul; 58(14):2973-7. PubMed ID: 9679957
[TBL] [Abstract][Full Text] [Related]
4. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.
Wang HQ; Altomare DA; Skele KL; Poulikakos PI; Kuhajda FP; Di Cristofano A; Testa JR
Oncogene; 2005 May; 24(22):3574-82. PubMed ID: 15806173
[TBL] [Abstract][Full Text] [Related]
5. Frequent activation of AKT2 kinase in human pancreatic carcinomas.
Altomare DA; Tanno S; De Rienzo A; Klein-Szanto AJ; Tanno S; Skele KL; Hoffman JP; Testa JR
J Cell Biochem; 2002; 87(4):470-6. PubMed ID: 14735903
[TBL] [Abstract][Full Text] [Related]
6. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
[TBL] [Abstract][Full Text] [Related]
8. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.
Altomare DA; Wang HQ; Skele KL; De Rienzo A; Klein-Szanto AJ; Godwin AK; Testa JR
Oncogene; 2004 Jul; 23(34):5853-7. PubMed ID: 15208673
[TBL] [Abstract][Full Text] [Related]
9. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.
Hayakawa J; Ohmichi M; Kurachi H; Kanda Y; Hisamoto K; Nishio Y; Adachi K; Tasaka K; Kanzaki T; Murata Y
Cancer Res; 2000 Nov; 60(21):5988-94. PubMed ID: 11085518
[TBL] [Abstract][Full Text] [Related]
11. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.
Asano T; Yao Y; Zhu J; Li D; Abbruzzese JL; Reddy SA
Oncogene; 2004 Nov; 23(53):8571-80. PubMed ID: 15467756
[TBL] [Abstract][Full Text] [Related]
12. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
Asselin E; Mills GB; Tsang BK
Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
[TBL] [Abstract][Full Text] [Related]
13. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.
Noske A; Kaszubiak A; Weichert W; Sers C; Niesporek S; Koch I; Schaefer B; Sehouli J; Dietel M; Lage H; Denkert C
Cancer Lett; 2007 Feb; 246(1-2):190-200. PubMed ID: 16584837
[TBL] [Abstract][Full Text] [Related]
14. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Kurose K; Zhou XP; Araki T; Cannistra SA; Maher ER; Eng C
Am J Pathol; 2001 Jun; 158(6):2097-106. PubMed ID: 11395387
[TBL] [Abstract][Full Text] [Related]
15. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation.
Okano J; Gaslightwala I; Birnbaum MJ; Rustgi AK; Nakagawa H
J Biol Chem; 2000 Oct; 275(40):30934-42. PubMed ID: 10908564
[TBL] [Abstract][Full Text] [Related]
16. Insulin-induced Drosophila S6 kinase activation requires phosphoinositide 3-kinase and protein kinase B.
Lizcano JM; Alrubaie S; Kieloch A; Deak M; Leevers SJ; Alessi DR
Biochem J; 2003 Sep; 374(Pt 2):297-306. PubMed ID: 12841848
[TBL] [Abstract][Full Text] [Related]
17. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells.
Neri LM; Borgatti P; Tazzari PL; Bortul R; Cappellini A; Tabellini G; Bellacosa A; Capitani S; Martelli AM
Mol Cancer Res; 2003 Jan; 1(3):234-46. PubMed ID: 12556562
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway.
Ghatak S; Misra S; Toole BP
J Biol Chem; 2002 Oct; 277(41):38013-20. PubMed ID: 12145277
[TBL] [Abstract][Full Text] [Related]
19. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.
Motti ML; Califano D; Troncone G; De Marco C; Migliaccio I; Palmieri E; Pezzullo L; Palombini L; Fusco A; Viglietto G
Am J Pathol; 2005 Mar; 166(3):737-49. PubMed ID: 15743786
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.
Edwards LA; Thiessen B; Dragowska WH; Daynard T; Bally MB; Dedhar S
Oncogene; 2005 May; 24(22):3596-605. PubMed ID: 15782140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
